Evidence map›Paper›PMID 39491717›Full record

Observational studyInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2025

Microbiological aspects and clinical impact of lower lung field tuberculosis: An observational cohort study in Peru.

Qi Tan, Chuan-Chin Huang, Roger Calderon, Leonid Lecca, Milagros Mendoza, Gabriela Reyes Rocha, Karen Tintaya, Ximena Tovar, Jia-Yih Feng, Sheng-Wei Pan and 4 more

Abstract readObservational Study
In one paragraph

Observational study in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qi TanDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Chuan-Chin HuangDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Roger CalderonPartners In Health-Socios En Salud Sucursal, Lima, Peru.
Leonid LeccaPartners In Health-Socios En Salud Sucursal, Lima, Peru.
Milagros MendozaPartners In Health-Socios En Salud Sucursal, Lima, Peru.
Gabriela Reyes RochaPartners In Health-Socios En Salud Sucursal, Lima, Peru.
Karen TintayaPartners In Health-Socios En Salud Sucursal, Lima, Peru.
Ximena TovarDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Jia-Yih FengDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Sheng-Wei PanDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Yen-Han TsengDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Jhong-Ru HuangDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Zibiao ZhangDivision of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Megan B MurrayDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: megan_murray@hms.harvard.edu.

Funding

Sequencing CoreU19AI109755 · NIAID · HARVARD MEDICAL SCHOOL · PI CHANDLER, DARRELL P, CULHANE, AEDIN C · 2014 to 2018
$29.1M
Metabolomics Core U19AI111224 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MOODY, DAVID BRANCH, MURRAY, MEGAN B · 2015 to 2021
$20.4M
Gerome Wide Association Study of Bacterial Determinants of Clinical Response in TuberculosisU19AI142793 · NIAID · HARVARD MEDICAL SCHOOL · PI MURRAY, MEGAN B · 2019 to 2023
$14.6M
Real-time surveillance to support dynamic and predictive models of MDR/XDR TBU19AI076217 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MURRAY, MEGAN B · 2007 to 2011
$13.5M
Epidemiology of multidrug-resistant tuberculosis in PeruU01AI057786 · NIAID · HARVARD MEDICAL SCHOOL · PI BECERRA, MERCEDES C · 2009 to 2010
$1.2M
NIAID NIH HHS U01 AI057786NIAID NIH HHS U19 AI076217NIAID NIH HHS U19 AI109755NIAID NIH HHS U19 AI111224NIAID NIH HHS U19 AI142793
6 · The paper itself

Abstract

objectivesApproximately 40% of tuberculosis (TB) cases remain undiagnosed globally. Lower lung field TB (LLF TB) presents atypically and is often misidentified as other lung diseases, leading to diagnostic delays in resource-limited settings. It may contribute to increased TB transmission and mortality. We aimed to identify microbiological determinants of LLF TB and evaluate treatment responses to optimize care.

methodsWe conducted an observational cohort study in Lima, Peru, enrolling adults with microbiologically confirmed pulmonary TB (PTB) diagnosed by GeneXpert MTB/RIF assay or sputum culture. Mycobacterium tuberculosis (MTB) lineage was determined using whole-genome sequencing. Due to the delayed chest radiograph changes in LLF TB compared to non-LLF TB, we measured changes in the St. George's Respiratory Questionnaire (SGRQ) score at 2-month treatment mark and evaluated World Health Organization-specified final treatment outcomes. We used logistic regression to evaluate the associations between LLF TB and microbiological determinants and treatment outcomes. We used linear regression to assess whether the change in SGRQ scores over the first 2 months of treatment varied by LLF TB status.

resultsAmong 1316 PTB patients, 84 (6%) had LLF TB. Compared to non-LLF TB patients, LLF TB patients were more likely to be smear-negative (adjusted odds ratio [aOR] [95% CI] = 2.04 [1.28-3.23], P = 0.002) and to be infected with Lineage 2 (aOR [95% CI] = 1.95 [95% CI: 1.07-3.41; P = 0.024]). People with LLF TB had less improvement in SGRQ scores after 2 months of treatment (adjusted score difference [95% CI] = -6.29 [-10.99 to -1.59], P = 0.009), while they experienced better final outcomes compared to non-LLF TB patients, though this difference did not reach statistical significance (aOR = 0.43 [95% CI: 0.13-1.05], P = 0.103).

conclusionPatients with LLF TB are more likely than those with upper lung lesions to be sputum-negative on conventional tests, to be infected with Lineage 2, and to show less clinical improvement after treatment.

Indexed as

Antitubercular AgentsMycobacterium tuberculosisSputumTuberculosis, PulmonaryAdultCohort StudiesFemaleHumansLungMaleMiddle AgedPeruTreatment OutcomeAntitubercular AgentsMTB lineage 2Pulmonary tuberculosisRadiographic localizationSGRQ scoreSputum smear-negative TB

Identifiers

PMID39491717
PMCPMC11694351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.